WUXI BIO(02269): It is recommended to repurchase shares on the open market for a total price not exceeding USD 400 million.

date
08:20 26/05/2026
avatar
GMT Eight
WuXi Biologics (02269) issued an announcement regarding the general mandate granted to the Company's shareholders at the annual general meeting held on June 6, 2025 for the repurchase of the Company's shares. According to the repurchase mandate, the Company is authorized to repurchase up to 407 million shares on the Stock Exchange of Hong Kong Limited, representing 10% of the total number of issued shares on the day of the annual general meeting of shareholders. On May 24, 2026, it was resolved to use the repurchase mandate, as well as (if applicable) any future general mandate approved by the shareholders at the Company's general meeting to repurchase shares, to repurchase shares on the open market at a total price not exceeding 400 million US dollars (proposed share repurchase).
WUXI BIO (02269) issued an announcement regarding the general mandate for the repurchase of the company's shares granted at the annual general meeting of shareholders held on June 6, 2025. Under the repurchase mandate, the company is authorized to repurchase up to 407 million shares on the Hong Kong Stock Exchange, representing 10% of the total number of shares issued on the date of the shareholders' annual meeting. On May 24, 2026, it has been resolved to utilize the repurchase mandate, as well as (if applicable) any future general mandate approved by shareholders at the company's general meeting to repurchase shares, to repurchase shares on the open market up to a total price not exceeding 400 million US dollars (recommended share buyback).